The Impact of Statins before High-Risk CABG on Postoperative Multiple Organ Function

Table 1

Characteristics of study population.

Variable	Preoperative statin therapy		-value
	YES (n = 503)	NO (n = 377)
Demographics
Age, mean (SD), y	65.4 (7.6)	64.8 (10.9)	0.349
Male sex, n (%)	348 (69.2)	177 (46.9)	<0.0001
BMI, mean (SD), kg/m2	25.1 (2.9)	24.7 (3.4)	0.061
BMI≥30, n (%)	24 (4.8)	25 (6.6)	0.239
Medical history
Hypertension, n (%)	301 (59.8)	162 (43.0)	<0.0001
HLP, n (%)	250 (49.7)	112 (29.7)	<0.0001
Diabetes mellitus, n (%)	282 (56.1)	89 (23.6)	<0.0001
Smoker, n (%)	149 (29.6)	91 (24.1)	0.079
COPD, n (%)	51 (10.1)	35 (9.3)	0.731
PVD, n (%)	116 (23.1)	72 (19.1)	0.116
Previous MI, n (%)	85 (16.9)	26 (7.0)	<0.0001
Previous CVA, n (%)	36 (7.2)	18 (4.8)	0.158
Previous AF, n (%)	68 (13.6)	62 (16.4)	0.250
LVEF, mean (SD), %	50.6 (15.1)	53.3 (19.1)	0.018
Moderate and poor LVEF (<50%) n (%)	242 (48.1)	154 (40.8)	0.028
Ventricular aneurysm, n (%)	53 (10.5)	25 (6.6)	0.055
Status
Urgent CABG, n (%)	21 (4.2)	26 (6.9)	0.053
Euroscore II	8.7 (4.4)	8.8 (2.9)	0.033
NYHA class, n (%)
II	310 (61.6)	255 (67.6)	0.076
III and IV	193 (38.4)	122 (32.4)	0.076
Off-pump	246 (48.9)	222 (58.9)	0.003
Duration of operation mean (SD), h	4.1 (6.4)	4.7 (1.4)	<0.0001
Medication at discharge
ACEI/ARB	112 (22.3)	53 (14.1)	0.002
CCB	64 (12.7)	40 (10.6)	0.345
Aspirin	385 (76.5)	274 (72.7)	0.209
Beta-blocker	295 (58.6)	156 (41.4)	<0.0001

CABG: coronary artery bypass grafting; LVEF: left ventricular ejection fraction; BMI: body mass index; MI: myocardial infarction TIA: prior transient ischemic attacks; CVA: cerebral vascular accident; PVD: previous peripheral vascular diseases AF: previous atrial fibrillation; COPD: previous chronic obstructive pulmonary diseases; NYHA : New York Heart Association; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; CCB: calcium channel blockers.